POET (POET) 6-K/A 21 Nov 23 Current report (foreign) (amended) Financial data

Cover

Cover	9 Months Ended
	Sep. 30, 2023
Cover [Abstract]
Document Type	6-K/A
Amendment Flag	true
Amendment Description	This Form 6-K/A amends the Form 6-K filed by POET Technologies Inc. on November 15, 2023 (the “Original Form 6-K”). This Amendment is being filed to provide the XBRL files that were omitted from the Original Form 6-K.
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-41319
Entity Registrant Name	POET TECHNOLOGIES INC.
Entity Central Index Key	0001437424
Entity Address, Address Line One	120 Eglinton Avenue East
Entity Address, Address Line Two	Ste. 1107
Entity Address, City or Town	Toronto
Entity Address, State or Province	ON
Entity Address, Country	CA
Entity Address, Postal Zip Code	M4P 1E2

Condensed Consolidated Statemen

Condensed Consolidated Statements of Financial Position - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current
Cash and cash equivalents (Note 2)	$ 4,476,478	$ 9,229,845
Accounts receivable (Note 3)		62,842
Prepaids and other current assets (Note 4)	462,922	275,507
Total current assets	4,939,400	9,568,194
Property and equipment (Note 6)	4,880,250	5,070,507
Patents and licenses (Note 7)	523,757	510,705
Right of use assets (Note 8)	365,681	241,047
Total assets	10,709,088	15,390,453
Current
Accounts payable and accrued liabilities (Note 9)	1,353,208	3,362,430
Lease liability (Note 8)	167,051	150,951
Contract liabilities (Note 3)	105,263	274,192
Covid-19 government support loans (Note 10)	29,428	29,520
Total current liabilities	1,654,950	3,817,093
Non-current lease liability (Note 8)	232,408	128,312
Total liabilities	1,887,358	3,945,405
Shareholders’ Equity
Share capital (Note 11(b))	165,205,349	151,206,539
Warrants and compensation options (Note 12)	670,115	5,905,642
Contributed surplus (Note 13)	54,446,740	51,016,808
Accumulated other comprehensive loss	(2,680,463)	(2,660,281)
Deficit	(208,820,011)	(194,023,660)
Total equity	8,821,730	11,445,048
Total equity and liabilities	$ 10,709,088	$ 15,390,453

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Deficit - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Profit or loss [abstract]
Revenue (Note 21)		$ 232,928	$ 358,226	$ 353,189
Operating expenses
Selling, marketing and administration (Note 20)	2,697,199	2,074,704	7,773,022	6,904,621
Research and development (Note 20)	2,449,800	2,361,991	7,505,863	7,227,372
Operating expenses	5,146,999	4,436,695	15,278,885	14,131,993
Operating loss before the following	(5,146,999)	(4,203,767)	(14,920,659)	(13,778,804)
Interest expense (Note 8)	(34,890)	(11,707)	(56,635)	(38,128)
Other income, including interest	45,448	57,429	180,943	119,728
Gain on the contribution of intellectual property to joint venture (Note 5)	527,857	496,115	527,857	496,115
Share of loss in joint venture (Note 5)	(527,857)	(379,368)	(527,857)	(1,555,650)
Net loss	(5,136,441)	(4,041,298)	(14,796,351)	(14,756,739)
Deficit, beginning of period	(203,683,570)	(183,702,411)	(194,023,660)	(172,986,970)
Deficit, end of period	$ (208,820,011)	$ (187,743,709)	$ (208,820,011)	$ (187,743,709)
Basic loss per share	$ (0.13)	$ (0.11)	$ (0.37)	$ (0.40)
Diluted loss per share	$ (0.13)	$ (0.11)	$ (0.37)	$ (0.40)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Profit or loss [abstract]
Net loss	$ (5,136,441)	$ (4,041,298)	$ (14,796,351)	$ (14,756,739)
Other comprehensive (loss) - net of income taxes
Exchange differences on translating foreign operations	(87,875)	(671,162)	(20,182)	(891,627)
Comprehensive loss	$ (5,224,316)	$ (4,712,460)	$ (14,816,533)	$ (15,648,366)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes in Shareholders' Equity - USD ($)	Issued capital [member]	Warrants [member]	Contributed Surplus [Member]	Accumulated other comprehensive income [member]	Retained earnings [member]
Balance at Dec. 31, 2021	$ 147,729,846	$ 5,328,455	$ 46,954,333	$ (2,053,917)	$ (172,986,970)
IfrsStatementLineItems [Line Items]
Funds from the exercise of warrants	284,437
Fair value assigned to warrants exercised	79,547
Funds from the exercise of stock options	418,845
Fair value of expired warrants	374,129
Funds from common shares issued through ATM Financing
Share issue costs
Common shares issued to settle accounts payable	40,029
Fair value assigned to warrants and compensation warrants exercised		(79,547)
Stock-based compensation			2,847,898
Fair value of stock options exercised			(374,129)
Other comprehensive (loss) - translation adjustment				(891,627)
Net loss					(14,756,739)
Balance at Sep. 30, 2022	148,926,833	5,248,908	49,428,102	(2,945,544)	(187,743,709)
Balance at Dec. 31, 2021	147,729,846	5,328,455	46,954,333	(2,053,917)	(172,986,970)
Balance at Dec. 31, 2022	151,206,539	5,905,642	51,016,808	(2,660,281)	(194,023,660)
IfrsStatementLineItems [Line Items]
Funds from the exercise of warrants	7,767,067
Fair value assigned to warrants exercised	4,418,783
Funds from the exercise of stock options	612,310
Fair value of expired warrants	538,168	(816,744)	816,744
Funds from common shares issued through ATM Financing	983,194
Share issue costs	(320,712)
Common shares issued to settle accounts payable
Fair value assigned to warrants and compensation warrants exercised		(4,418,783)
Stock-based compensation			3,151,356
Fair value of stock options exercised			(538,168)
Other comprehensive (loss) - translation adjustment				(20,182)
Net loss					(14,796,351)
Balance at Sep. 30, 2023	$ 165,205,349	$ 670,115	$ 54,446,740	$ (2,680,463)	$ (208,820,011)

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
OPERATING ACTIVITIES
Net loss	$ (14,796,351)	$ (14,756,739)
Adjustments for:
Depreciation of property and equipment (Note 6)	1,221,090	770,080
Amortization of right of use asset (Note 8)	129,122	123,345
Amortization of patents and licenses (Note 7)	66,058	58,715
Non-cash interest (Note 8)	40,067	38,128
Stock-based compensation (Note 13)	3,151,356	2,847,898
Gain on contribution of intellectual property to joint venture (Note 5)	(527,857)	(496,115)
Share of loss in joint venture (Note 5)	527,857	1,555,650
Total adjustments to reconcile profit (loss)	(10,188,658)	(9,859,038)
Net change in non-cash working capital accounts:
Accounts receivable	62,000
Prepaid and other current assets	(189,988)	129,515
Accounts payable and accrued liabilities	(2,004,401)	(249,000)
Contract liabilities	(165,263)	389,561
Cash flows from operating activities	(12,486,310)	(9,588,962)
INVESTING ACTIVITIES
Sale of short-term investments		6,366,828
Purchase of property and equipment (Note 6)	(1,132,514)	(1,365,917)
Purchase of patents and licenses (Note 7)	(79,110)	(62,475)
Cash flows from investing activities	(1,211,624)	4,938,436
FINANCING ACTIVITIES
Issue of common shares, net of share issue costs (Note 11)	9,041,859	703,282
Payment of lease liability (Note 8)	(173,025)	(159,758)
Cash flows from financing activities	8,868,834	543,524
EFFECT OF EXCHANGE RATE CHANGES ON CASH	75,733	(565,625)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(4,753,367)	(4,672,627)
CASH AND CASH EQUIVALENTS, beginning of period	9,229,845	14,941,775
CASH AND CASH EQUIVALENTS, end of period	$ 4,476,478	$ 10,269,148

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
DESCRIPTION OF BUSINESS	1. DESCRIPTION OF BUSINESS POET Technologies Inc. is incorporated in the Province of Ontario. POET Technologies Inc. and its subsidiaries (the “Company”) design and develop the POET Optical Interposer and Photonic Integrated Circuits for the data centre, tele-communications and artificial intelligence markets. The Company’s head office is located at 120 Eglinton Avenue East, Suite 1107, Toronto, Ontario, Canada M4P 1E2. These condensed unaudited consolidated financial statements of the Company were approved by the Board of Directors of the Company on November 14, 2023. As at September 30, 2023, the Company has accumulated losses of $ (208,820,011) 3,284,450 12,486,310 To address the future funding requirements, management has undertaken the following initiatives: 1. Initiated an at-the-market (“ATM”) equity offering program to raise capital by selling shares directly to the public in the open market. The Canadian only ATM was terminated on August 5, 2023 while the United States-only ATM program was temporarily suspended in September 2023. 2. Raised gross proceeds of $ 983,194 3. Established a strict budgetary process with a focus on maintaining an appropriate level of corporate overhead in line with the Company’s available cash resources. Although the Company has been successful in obtaining equity and similar financings in the past, there is no assurance that it will be able do so in the future. The Company does however, have a reasonable expectation that it will be able to manage its finances in order to continue its operations.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES These condensed unaudited consolidated financial statements of the Company and its subsidiaries were prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”). These condensed unaudited consolidated financial statements do not include all of the information required for full annual financial statements and should be read in conjunction with the consolidated audited financial statements for the year ended December 31, 2022. The preparation of financial statements in accordance with International Accounting Standards (“IAS”) 34 Interim Financial Reporting, requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company’s accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed below: Basis of presentation These consolidated financial statements include the accounts of POET Technologies Inc. and its subsidiaries; ODIS Inc. (“ODIS”), Opel Solar Inc. (“OPEL”), BB Photonics Inc.,(“BB Photonics”), POET Technologies Pte Ltd. (“PTS”) and POET Optoelectronics Shenzhen Co. Ltd. (“POET Shenzhen”). All intercompany balances and transactions have been eliminated on consolidation. POET TECHNOLOGIES INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars) 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Foreign currency translation These condensed unaudited consolidated financial statements are presented in U.S. dollars (“USD”), which is the Company’s presentation currency. Items included in the financial statements of each of the Company’s subsidiaries are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transaction. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities not denominated in the functional currency of an entity are recognized in the statement of operations and deficit. Assets and liabilities of entities with functional currencies other than U.S. dollars are translated into the presentation currency at the year end rates of exchange, and the results of their operations are translated at average rates of exchange for the year. The resulting translation adjustments are included in accumulated other comprehensive loss in shareholders’ equity. Additionally, foreign exchange gains and losses related to certain intercompany loans that are permanent in nature are included in accumulated other comprehensive loss. Elements of equity are translated at historical rates. Financial Instruments Financial assets held with an objective to hold assets in order to collect contractual cash flows which arise on specified dates that are solely principal and interest are measured at amortised cost using the effective interest method. Debt investments held with an objective to hold both assets in order to collect contractual cash flows which arise on specified dates that are solely principal and interest as well as selling the asset on the basis of fair value are measured at FVTOCI. All other financial assets are classified and measured at fair value through profit or loss (“FVTPL”). Financial liabilities are classified as either FVTPL or other financial liabilities, and the portion of the change in fair value that relates to the Company’s credit risk is presented in other comprehensive loss. Instruments classified as FVTPL are measured at fair value with unrealized gains and losses recognized in net loss. Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Transaction costs that are directly attributable to the acquisition or issuance of financial assets and financial liabilities, other than financial assets and financial liabilities classified as FVTPL, are added to or deducted from the fair value on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities classified as FVTPL are recognized immediately in consolidated net loss. Financial assets The Company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and it does not retain control of the financial asset. Any interest in transferred financial assets that is created or retained by the Company is recognized as a separate asset or liability. Financial liabilities A financial liability is derecognized from the balance sheet when it is extinguished, that is, when the obligation specified in the contract is either discharged, cancelled or expires. Where there has been an exchange between an existing borrower and lender of debt instruments with substantially different terms, or there has been a substantial modification of the terms of an existing financial liability, this transaction is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. A gain or loss from extinguishment of the original financial liability is recognized in profit or loss. The Company’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, contract liabilities and covid-19 government support loans. POET TECHNOLOGIES INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars) 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) The following table outlines the classification of financial instruments under IFRS 9: SCHEDULE OF CLASSIFICATION OF FINANCIAL INSTRUMENTS Financial Assets Cash and cash equivalents Amortized cost Accounts receivable Amortized cost Financial Liabilities Accounts payable and accrued liabilities Amortized cost Contract liabilities Amortized cost Covid-19 government support loans Amortized cost Convertible debentures are accounted for as a compound financial instrument with a debt component and a separate equity component. The debt component of these compound financial instruments is measured at fair value on initial recognition by discounting the stream of future interest and principal payments at the rate of interest prevailing at the date of issue for instruments of similar term and risk. The debt component is subsequently deducted from the total carrying value of the compound instrument to derive the equity component. The debt component is subsequently measured at amortized cost using the effective interest rate method. Interest expense based on the coupon rate of the debenture and the accretion of the liability component to the amount that will be payable on redemption are recognized through profit or loss as a finance cost. Cash and cash equivalents Cash and cash equivalents consist of cash in current accounts of $ 1,168,483 1,981,765 3,307,995 7,248,080 4% 4.2% Property and equipment Property and equipment are recorded at cost. Depreciation is calculated based on the estimated useful life of the asset using the following method and useful lives: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED LIFE Machinery and equipment Straight Line, 5 Leasehold improvements Straight Line, 5 Office equipment Straight Line, 3 5 Patents and licenses Patents and licenses are recorded at cost and amortized on a straight line basis over 12 Revenue recognition Revenue is measured based on the consideration specified in a contract with a customer and excludes amounts collected on behalf of third parties. The Company recognizes revenue when it transfers control over a product or service to a customer. Sale of goods Revenue from the sale of goods is recognized, net of discounts and customer rebates, at the point in time the transfer of control of the related products has taken place as specified in the sales contract and collectability is reasonably assured. POET TECHNOLOGIES INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars) 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Service revenue The Company provides contract services, primarily in the form of non-recurring revenue (“NRE”) where control is passed to the customer over time. The contracts generally provide agreed upon milestones for customer payment which include but are not limited to the delivery of sample products, design reports and test reports. The customer makes payment when it has approved the delivery of the milestone. The Company must determine if the contract is made up of a series of independent performance obligations or a single performance obligation. Where NRE contracts contain multiple performance obligations for which a standalone transaction price can be assessed, revenue is recognized as each performance obligation is satisfied. Where NRE contracts contain a single performance obligation to be settled over time, revenue is recognized progressively based on the output method. Other income Interest income Interest income on cash and cash equivalents and short-term investments is recognized as earned using the effective interest method. Wage subsidies Wages subsidies received from the Singaporean government are netted against payroll costs on the consolidated statements of operations and deficit. Government Grants Loans received exclusively from governmental agencies to support the Company throughout the COVID-19 pandemic qualify to be forgiven if certain conditions are met. Forgiveness of COVID-19 related loans will be recognized as other income on the consolidated statements of operations and deficit. Stock-based compensation Stock options and warrants awarded to non employees are measured using the fair value of the goods or services received unless that fair value cannot be estimated reliably, in which case measurement is based on the fair value of the stock options. Stock options and warrants awarded to employees are accounted for using the fair value method. The fair value of such stock options and warrants granted is recognized as an expense on a proportionate basis consistent with the vesting features of each tranche of the grant. The fair value is calculated using the Black-Scholes option pricing model with assumptions applicable at the date of grant. Loss per share Basic loss per share, net of taxes is calculated by dividing net loss by the weighted average number of common shares outstanding during the year. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding during the period after giving effect to potentially dilutive financial instruments. The dilutive effect of stock options and warrants is determined using the treasury stock method. Joint Venture A joint arrangement is an arrangement among two or more parties where the parties are bound by a contractual arrangement and the contractual arrangement gives the parties joint control of the arrangement. A joint venture is a form of joint arrangement where an entity is independently formed and the parties jointly have rights to the net assets of the arrangement and therefore account for their interests under the equity method. POET TECHNOLOGIES INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

ACCOUNTS RECEIVABLE AND CONTRAC

ACCOUNTS RECEIVABLE AND CONTRACT LIABILITIES	9 Months Ended
	Sep. 30, 2023
Accounts Receivable And Contract Liabilities
ACCOUNTS RECEIVABLE AND CONTRACT LIABILITIES	3. ACCOUNTS RECEIVABLE AND CONTRACT LIABILITIES Revenue Contract Balances SCHEDULE OF REVENUE CONTRACT BALANCES Contract Receivables Liabilities Opening balance, January 1, 2023 $ 62,842 $ (274,192 ) Changes due to payment, fulfillment of performance obligations or revenues recognized (62,842 ) 157,500 Effect of changes in foreign exchange rates - 11,429 Balance, September 30, 2023 $ - $ (105,263 )

PREPAIDS AND OTHER CURRENT ASSE

PREPAIDS AND OTHER CURRENT ASSETS	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
PREPAIDS AND OTHER CURRENT ASSETS	4. PREPAIDS AND OTHER CURRENT ASSETS The following table reflects the details of prepaids and other current assets: SCHEDULE OF PRREPAIDS AND OTHER CURRENT ASSETS September 30, December 31, 2023 2022 Sales tax recoverable and other current assets $ 78,005 $ 128,321 Prepaid expenses 356,814 147,186 Equipment deposit 28,103 - Prepaids and other current assets $ 462,922 275,507

JOINT VENTURE

JOINT VENTURE	9 Months Ended
	Sep. 30, 2023
Joint Venture
JOINT VENTURE	5. JOINT VENTURE The Company’s contribution of intellectual property to Super Photonics Xiamen Co., Ltd (“SPX”) was independently valued at $ 22,500,000 4,868,225 17,631,775 21.6 78.4 SPX was determined to be a joint venture as both Sanan IC and POET exercise joint control over SPX. All relevant activity of SPX require unanimous consent. Summarized financial information of the joint venture is as follows: SCHEDULE OF FINANCIAL INFORMATION OF JOINT VENTURE September 30, December 31, 2023 2022 Current assets $ 1,315,146 1,951,654 Intangible assets 16,199,173 18,708,065 Liabilities (154,720 ) (180,897 ) Owners Equity (17,359,599 ) (20,478,822 ) Net loss for the nine months ended September 30, 2023 and 2022 $ 2,914,956 $ 1,329,525 The Company recognizes its share of SPX’s profits or losses using the equity method. On a weighted average basis, the Company’s share of the net operating loss was 79.9 (2,329,103) (527,857) 87.9 (1,555,650) POET TECHNOLOGIES INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
PROPERTY AND EQUIPMENT	6. PROPERTY AND EQUIPMENT SCHEDULE OF PROPERTY AND EQUIPMENT Equipment not Leasehold Machinery and Office in service improvements equipment equipment Total Cost Balance, January 1, 2022 $ - $ 117,115 $ 4,830,020 $ 183,269 $ 5,130,404 Additions, net of returns 1,902,713 - 1,087,414 21,435 3,011,562 Reclassification (141,702 ) - 162,917 (21,215 ) - Effect of changes in foreign exchange rates 54,898 6,544 11,270 (5,586 ) 67,126 Balance, December 31, 2022 1,815,909 123,659 6,091,621 177,903 8,209,092 Property and equipment, cost, Beginning balance 1,815,909 123,659 6,091,621 177,903 8,209,092 Additions 206,378 - 913,731 12,405 1,132,514 Reclassification (2,016,605 ) - 2,016,605 - - Effect of changes in foreign exchange rates, net (5,682 ) (883 ) (99,377 ) 4,261 (101,681 ) Balance, September 30, 2023 - 122,776 8,922,580 194,569 9,239,925 Property and equipment, cost, Ending balance - 122,776 8,922,580 194,569 9,239,925 Accumulated Depreciation Balance, January 1, 2022 - 29,526 1,930,726 105,918 2,066,170 Depreciation - 24,079 1,000,085 30,100 1,054,264 Effect on changes in foreign exchange rates - 2,529 27,727 (12,105 ) 18,151 Balance, December 31, 2022 - 56,134 2,958,538 123,913 3,138,585 Property and equipment, accumulated depreciation, Beginning balance - 56,134 2,958,538 123,913 3,138,585 Depreciation for the period - 18,544 1,178,524 24,022 1,221,090 Balance, September 30, 2023 - 74,678 4,137,062 147,935 4,359,675 Property and equipment, accumulated depreciation, Ending balance - 74,678 4,137,062 147,935 4,359,675 Carrying Amounts At December 31, 2022 $ 1,815,909 $ 67,525 $ 3,133,083 $ 53,990 $ 5,070,507 Property and equipment, carrying amounts, Beginning balance $ 1,815,909 $ 67,525 $ 3,133,083 $ 53,990 $ 5,070,507 At September 30, 2023 $ - $ 48,098 $ 4,785,518 $ 46,634 $ 4,880,250 Property and equipment, carrying amounts, Ending balance 48,098 4,785,518 46,634 4,880,250

PATENTS AND LICENSES

PATENTS AND LICENSES	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
PATENTS AND LICENSES	7. PATENTS AND LICENSES SCHEDULE OF PATENTS AND LICENSES Cost Balance, January 1, 2022 $ 996,461 Additions 62,475 Balance, December 31, 2022 1,058,936 Patents and licenses, cost, beginning 1,058,936 Additions 79,110 Balance, September 30, 2023 1,138,046 Patents and licenses, cost, ending 1,138,046 Accumulated Depreciation Balance, January 1, 2022 467,985 Amortization 80,246 Balance, December 31, 2022 548,231 Patents and licenses, accumulated amortization, beginning 548,231 Amortization during the period 66,058 Balance, September 30, 2023 614,289 Patents and licenses, accumulated amortization, ending 614,289 Carrying Amounts At December 31, 2022 $ 510,705 Patents and licenses, carrying amounts, beginning $ 510,705 At September 30, 2023 $ 523,757 Patents and licenses, carrying amounts, ending 523,757 POET TECHNOLOGIES INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

RIGHT OF USE ASSET AND LEASE LI

RIGHT OF USE ASSET AND LEASE LIABILITY	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
RIGHT OF USE ASSET AND LEASE LIABILITY	8. RIGHT OF USE ASSET AND LEASE LIABILITY The Company recognizes a lease liability and right of use asset relating to its commercial leases. The lease liability is measured at the present value of the remaining lease payments, discounted using the Company’s incremental borrowing rate of 12 SCHEDULE OF RIGHT OF USE ASSET AND LEASE LIABILITY Right of use asset Building Cost Balance, January 1, 2022 $ 649,110 Lease modification 81,542 Balance, December 31, 2022 730,652 Right of use asset, Cost, Beginning balance 730,652 Additions 260,352 Balance, September 30, 2023 991,004 Right of use asset, Cost, Ending balance 991,004 Accumulated Amortization Balance, January 1, 2022 322,220 Amortization 158,648 Effect of changes in foreign exchange rates 8,737 Balance, December 31, 2022 489,605 Right of use asset, Accumulated Amortization, Beginning balance 489,605 Amortization during the period 129,122 Effect of changes in foreign exchange rates, net 6,596 Balance, September 30, 2023 625,323 Right of use asset, Accumulated Amortization, Ending balance 625,323 Carrying Amounts At December 31, 2022 $ 241,047 Right of use asset, Carrying Amounts, Beginning balance $ 241,047 At September 30, 2023 $ 365,681 Right of use asset, Carrying Amounts, Ending balance 365,681 Lease liability Balance, January 1, 2022 $ 359,348 Interest expense 49,738 Lease payments (204,518 ) Lease modification 81,542 Effect of changes in foreign exchange rates (6,847 ) Balance, December 31, 2022 279,263 Lease liability, Beginning balance 279,263 Additions 260,352 Interest expense (1) 40,067 Lease payments (172,820 ) Effect of changes in foreign exchange rates, net (7,403 ) Balance, September 30, 2023 $ 399,459 Lease liability, Ending balance 399,459 (1) The Company paid $ 16,568

ACCOUNTS PAYABLE AND ACCRUED LI

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	9. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES September 30, December 31, 2023 2022 Trade payable $ 848,075 $ 2,723,531 Payroll related liabilities 449,465 452,751 Accrued liabilities 55,668 186,148 Total accounts payable and accrued liabilities $ 1,353,208 $ 3,362,430 POET TECHNOLOGIES INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

COVID-19 GOVERNMENT SUPPORT LOA

COVID-19 GOVERNMENT SUPPORT LOANS	9 Months Ended
	Sep. 30, 2023
Covid-19 Government Support Loans
COVID-19 GOVERNMENT SUPPORT LOANS	10. COVID-19 GOVERNMENT SUPPORT LOANS On April 9, 2020, the Canadian government launched the Canada Emergency Business Account (“CEBA”) which is intended to support businesses during COVID-19 by providing interest free financing of up to $ 29,428 40,000 the Company received a loan in the amount of $ 29,428 29,520 5

SHARE CAPITAL

SHARE CAPITAL	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
SHARE CAPITAL	11. SHARE CAPITAL (a) AUTHORIZED Unlimited number of common shares One special voting share (b) COMMON SHARES ISSUED SCHEDULE OF COMMON SHARES ISSUED Number of Amount Balance, January 1, 2022 36,494,228 $ 147,729,846 Shares issued to settle accounts payable 5,422 40,029 Funds from common shares issued on private placement 1,126,635 3,184,332 Fair value of warrants issued on private placement - (656,734 ) Share issue costs - (247,892 ) Funds from the exercise of stock options 143,437 418,845 Fair value of stock options exercised - 374,129 Funds from the exercise of warrants and compensation warrants 72,500 284,437 Fair value of warrants and compensation warrants exercised - 79,547 Adjustment for 10 for 1 share consolidation (272 ) - Balance, December 31, 2022 37,841,950 151,206,539 Funds from the exercise of stock options 245,606 612,310 Fair value of stock options exercised - 538,168 Funds from the exercise of warrants 2,364,066 7,767,067 Fair value of warrants exercised - 4,418,783 Funds from Common shares issued through ATM financing 227,673 983,194 Share issue costs - (320,712 ) Balance, September 30, 2023 40,679,295 $ 165,205,349 During the nine months ended September 30, 2023, the Company raised gross proceeds of $ 983,194 227,673 30 3 29,486 291,226 POET TECHNOLOGIES INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

WARRANTS AND COMPENSATION OPTIO

WARRANTS AND COMPENSATION OPTIONS	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
WARRANTS AND COMPENSATION OPTIONS	12. WARRANTS AND COMPENSATION OPTIONS The following table reflects the continuity of warrants and compensation options: SCHEDULE OF WARRANTS AND COMPENSATION OPTIONS Historical Number of Average Exercise Price Warrants/ Compensation options Historical Fair value Balance, January 1, 2022 $ 7.10 3,021,353 $ 5,328,455 Fair value of warrant issued on private placement 1.17 563,318 656,734 Historical fair value assigned to warrants exercised 3.90 (72,500 ) (79,547 ) Balance, December 31, 2022 6.15 3,512,171 5,905,642 Historical fair value assigned to warrants exercised 3.27 (2,364,066 ) (4,418,783 ) Historical fair value of warrants expired 4.50 (584,787 ) (816,744 ) Balance, September 30, 2023 $ 3.64 563,318 $ 670,115

STOCK OPTIONS AND CONTRIBUTED S

STOCK OPTIONS AND CONTRIBUTED SURPLUS	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
STOCK OPTIONS AND CONTRIBUTED SURPLUS	13. STOCK OPTIONS AND CONTRIBUTED SURPLUS Stock Options On June 30, 2023, shareholders of the Company approved a fixed 20 8,056,055 20 Stock option transactions and the number of stock options outstanding were as follows: SCHEDULE OF STOCK OPTIONS OUTSTANDING Number of Historical Balance, January 1, 2022 4,959,617 $ 4.40 Expired/cancelled (117,438 ) 6.02 Exercised (143,437 ) 2.85 Granted 2,043,083 3.32 Balance, December 31, 2022 6,741,825 4.10 Expired/cancelled (182,750 ) 4.66 Exercised (245,606 ) 2.49 Granted 1,002,170 4.11 Balance, September 30, 2023 7,315,639 $ 4.14 POET TECHNOLOGIES INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars) 13. STOCK OPTIONS AND CONTRIBUTED SURPLUS (Continued) During the nine months ended September 30, 2023, the Company granted 1,002,170 242,939 4.11 6.39 During the nine months ended September 30, 2023, the Company recorded stock-based compensation of $ 3,151,356 2,847,898 The stock options granted were valued using the Black-Scholes option pricing model using the following assumptions: SCHEDULE OF STOCK OPTIONS ASSUMPTIONS Nine Months Ended September 30, 2023 2022 Weighted average exercise price $ 4.11 $ 6.39 Weighted average risk-free interest rate 2.88 3.48 % 1.80 3.5 % Weighted average dividend yield 0 % 0 % Weighted average volatility 82.45 % 84.74 % Weighted average estimated life 10 10 Weighted average share price $ 4.11 $ 6.39 Share price on the various grant dates: $ 4.05 4.63 $ 4.37 6.86 Weighted average fair value $ 3.42 $ 5.41 The underlying expected volatility was determined by reference to the Company’s historical share price movements, its dividend policy and dividend yield and past experience relating to the expected life of granted stock options. The weighted average remaining contractual life and weighted average exercise price of options outstanding and of options exercisable as at September 30, 2023 are as follows: SCHEDULE OF WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE AND WEIGHTED AVERAGE EXERCISE PRICE OF OPTIONS Options Outstanding Options Exercisable Exercise Range Number Historical Weighted Average Weighted Average Remaining Number Historical $ 0.82 1.93 7,000 $ 1.91 4.84 7,000 $ 1.91 $ 1.93 2.76 1,873,823 $ 2.38 6.42 1,267,829 $ 2.28 $ 2.76 8.84 5,434,816 $ 4.31 7.46 3,208,513 $ 4.21 7,315,639 $ 3.81 7.20 4,483,342 $ 3.66 POET TECHNOLOGIES INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

LOSS PER SHARE

LOSS PER SHARE	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
LOSS PER SHARE	14. LOSS PER SHARE SCHEDULE OF INCOME (LOSS) PER SHARE 2023 2022 2023 2022 Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Numerator Net loss $ (5,136,441 ) $ (4,041,298 ) $ (14,796,351 ) $ (14,756,739 ) Denominator Weighted average number of common shares outstanding - basic and diluted 40,565,912 36,672,390 39,716,526 36,589,778 Basic and diluted loss per share $ (0.13 ) $ (0.11 ) $ (0.37 ) $ (0.40 ) The effect of common share purchase options, warrants and broker warrants on the net loss is not reflected as they are anti-dilutive.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
COMMITMENTS AND CONTINGENCIES	15. COMMITMENTS AND CONTINGENCIES The Company has operating leases on four facilities; head office located in Toronto, Canada, design and testing operations located in Allentown, Pennsylvania (formerly in San Jose, California) and operating facilities located in Singapore and China. The Company’s design and testing operations was initiated on April 1, 2021 and expires on September 30, 2025. The lease on the Company’s operating facilities in Singapore terminated on May 31, 2023. The lease was renewed on June 1, 2023 and expires on March 31, 2027. The lease on the Company’s operating facilities in China was initiated in November 19, 2021 and expires on November 18, 2023. The lease on the operating facility in China has since been renewed for another three year term, expiring on November 18, 2026. As of September 30, 2023, the Company’s head office was on a month to month lease term. Remaining minimum annual rental payments to the lease expiration dates are as follows: SCHEDULE OF REMAINING ANNUAL RENTAL PAYMENTS LEASE October 1, 2023 to December 31, 2023 $ 66,019 2024 and beyond 457,230 $ 523,249

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
RELATED PARTY TRANSACTIONS	16. RELATED PARTY TRANSACTIONS Compensation to key management personnel were as follows: SCHEDULE OF COMPENSATION TO KEY MANAGEMENT PERSONNEL Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Salaries $ 499,160 $ 504,099 $ 1,505,341 $ 1,472,296 Share-based payments ( 1 ) 493,952 351,751 1,386,341 1,223,152 Total $ 993,112 $ 855,850 $ 2,891,682 $ 2,695,448 (1) Share-based payments are the fair value of options granted to key management personnel and expensed during the various periods as calculated using the Black-Scholes model. All transactions with related parties have occurred in the normal course of operations and are measured at the exchange amounts, which are the amounts of consideration established and agreed to by the related parties. POET TECHNOLOGIES INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

SEGMENT INFORMATION

SEGMENT INFORMATION	9 Months Ended
	Sep. 30, 2023
SEGMENT INFORMATION	17. SEGMENT INFORMATION The Company and its subsidiaries operate in a single segment; the design, manufacture and sale of semi-conductor products and services for commercial applications. The Company’s operating and reporting segment reflects the management reporting structure of the organization and the manner in which the chief operating decision maker regularly assesses information for decision making purposes, including the allocation of resources. A summary of the Company’s operations is below: OPEL, ODIS, POET Shenzhen and PTS OPEL, ODIS, POET Shenzhen and PTS are the designers and developers of the POET Optical Interposer platform and optical engines based on the POET Optical Interposer platform. BB Photonics BB Photonics developed photonic integrated components for the datacom and telecom markets utilizing embedded dielectric technology that enabled the partial integration of active and passive devices into photonic integrated circuits. BB Photonics’ operation is currently dormant. On a consolidated basis, the Company operates geographically in China and Singapore (collectively “Asia”), the United States and Canada. Geographical information is as follows: SCHEDULE OF GEOGRAPHICAL INFORMATION 2023 As of September 30, Asia US Canada Consolidated Current assets $ 165,961 $ 417,624 $ 4,355,815 $ 4,939,400 Property and equipment 4,300,857 579,393 - 4,880,250 Patents and licenses - 523,757 - 523,757 Right of use assets 242,168 123,513 - 365,681 Total Assets $ 4,708,986 $ 1,644,287 $ 4,355,815 $ 10,709,088 For the Nine Months Ended September 30, Asia US Canada Consolidated Revenue $ 358,226 $ - $ - $ 358,226 Selling, marketing and administration $ (2,025,536 ) $ (4,542,054 ) $ (1,205,432 ) $ (7,773,022 ) Research and development (4,646,713 ) (2,739,509 ) (119,641 ) (7,505,863 ) Interest expense (20,243 ) (36,392 ) - (56,635 ) Share of loss in joint venture (527,857 ) - - (527,857 ) Gain from contribution of IP to joint venture 527,857 - - 527,857 Other income, including Interest - - 180,943 180,943 Net loss $ (6,334,266 ) $ (7,317,955 ) $ (1,144,130 ) $ (14,796,351 ) As of December 31, Asia US Canada Consolidated 2022 As of December 31, Asia US Canada Consolidated Current assets $ 664,658 $ 133,501 $ 8,770,035 $ 9,568,194 Property and equipment 4,496,734 573,773 - 5,070,507 Patents and licenses - 510,705 - 510,705 Right of use assets 55,775 185,272 - 241,047 Total Assets $ 5,217,167 $ 1,403,251 $ 8,770,035 $ 15,390,453 POET TECHNOLOGIES INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars) 17. SEGMENT INFORMATION (continued) For the Nine Months Ended September 30, Asia US Canada Consolidated Revenue $ 353,189 $ - $ - $ 353,189 Selling, marketing and administration $ (1,549,628 ) $ (4,280,844 ) $ (1,074,149 ) $ (6,904,621 ) Research and development (3,992,505 ) (3,099,397 ) (135,470 ) (7,227,372 ) Interest (14,429 ) (23,699 ) - (38,128 ) Share of loss in joint venture (1,555,650 ) - - (1,555,650 ) Gain from contribution of IP to joint venture 496,115 - - 496,115 Other income, including interest - - 119,728 119,728 Net loss $ (6,262,908 ) $ (7,403,940 ) $ (1,089,891 ) $ (14,756,739 )

FINANCIAL INSTRUMENTS AND RISK

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
FINANCIAL INSTRUMENTS AND RISK MANAGEMENT	18. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT The Company’s financial instruments consist of cash and cash equivalents, short-term investments, covid-19 government support loans and accounts payable and accrued liabilities. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest risk arising from these financial instruments. The Company estimates that carrying value of these instruments approximates fair value due to their short term nature. The Company has classified financial assets and (liabilities) as follows: SCHEDULE OF CLASSIFIED FINANCIAL ASSETS AND LIABILITIES September 30, December 31, 2023 2022 Cash and cash equivalents, measured at amortized cost: Cash and cash equivalents $ 4,476,478 $ 9,229,845 Receivables, measured at amortized cost: Accounts receivable $ - $ 62,842 Other liabilities, measured at amortized cost: Accounts payable and accrued liabilities $ (1,353,208 ) $ (3,362,430 ) Covid-19 government support loans $ (29,428 ) $ (29,520 ) Contract liabilities $ (105,263 ) $ (274,192 ) Exchange Rate Risk The functional currency of each of the entities included in the accompanying consolidated financial statements is the local currency where the entity is domiciled. Functional currencies include the Chinese Yuan, US, Singapore and Canadian dollar. Most transactions within the entities are conducted in functional currencies. As such, none of the entities included in the consolidated financial statements engage in hedging activities. The Company is exposed to a foreign currency risk when its subsidiaries hold current assets or current liabilities in currencies other than its functional currency. A 10 8,200 Liquidity Risk The Company currently does not maintain credit facilities. The Company’s existing cash and cash resources are not sufficient to fund operating and investing activities beyond one year from the date of these unaudited condensed consolidated financial statements. POET TECHNOLOGIES INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

CAPITAL MANAGEMENT

CAPITAL MANAGEMENT	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
CAPITAL MANAGEMENT	19. CAPITAL MANAGEMENT In the management of capital, the Company includes shareholders’ equity (excluding accumulated other comprehensive loss and deficit) and cash and cash equivalents and short-term investments. The components of capital on September 30, 2023 were: SCHEDULE OF COMPONENTS OF CAPITAL Cash and cash equivalents and short-term investments $ 4,476,478 Shareholders’ equity $ 220,322,204 The Company’s objective in managing capital is to ensure that financial flexibility is present to increase shareholder value through growth and responding to changes in economic and/or market conditions; to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business and to safeguard the Company’s ability to obtain financing should the need arise. In maintaining its capital, the Company has a strict investment policy which includes investing its surplus capital only in highly liquid, highly rated financial instruments. The Company reviews its capital management approach on an ongoing basis.

EXPENSES

EXPENSES	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
EXPENSES	20. EXPENSES Research and development costs can be analysed as follows: SCHEDULE OF EXPENSES BY NATURE 2023 2022 2023 2022 Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Wages and benefits $ 1,074,549 $ 1,042,347 $ 3,221,450 $ 2,990,224 Subcontract fees 314,296 400,475 1,632,010 1,720,487 Stock-based compensation 406,536 477,224 1,109,171 1,280,702 Supplies 654,419 441,945 1,543,232 1,235,959 Research and development costs $ 2,449,800 $ 2,361,991 $ 7,505,863 $ 7,227,372 Selling, marketing and administration costs can be analysed as follows: Stock-based compensation $ 845,112 $ 403,572 $ 2,042,185 $ 1,567,196 Wages and benefits 640,241 646,349 1,973,231 1,983,180 General expenses 387,183 435,990 1,375,911 1,558,810 Professional fees 273,905 203,778 842,403 743,075 Depreciation and amortization 508,484 336,446 1,416,271 952,141 Rent and facility costs 42,274 48,569 123,021 100,219 Selling, marketing and administration costs $ 2,697,199 $ 2,074,704 $ 7,773,022 $ 6,904,621

REVENUE

REVENUE	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
REVENUE	21. REVENUE Disaggregated Revenues The Company disaggregates revenue by timing of revenue recognition, that is, at a point in time and revenue over time. During the three and nine months ended September 30, 2023, the Company recognized nil 358,226 232,928 353,189

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
SUBSEQUENT EVENTS	22. SUBSEQUENT EVENTS On November 2, 2023, the Company commenced an underwritten public offering in the United States (the “U.S. Offering”). Concurrently, the Company also commenced an offering in Canada (the “LIFE Offering” and, together with the U.S. Offering, the “Offering”). The Offering consists of common shares of the Company and warrants to purchase common shares and is subject to market conditions.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
Basis of presentation	Basis of presentation These consolidated financial statements include the accounts of POET Technologies Inc. and its subsidiaries; ODIS Inc. (“ODIS”), Opel Solar Inc. (“OPEL”), BB Photonics Inc.,(“BB Photonics”), POET Technologies Pte Ltd. (“PTS”) and POET Optoelectronics Shenzhen Co. Ltd. (“POET Shenzhen”). All intercompany balances and transactions have been eliminated on consolidation. POET TECHNOLOGIES INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars) 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Foreign currency translation	Foreign currency translation These condensed unaudited consolidated financial statements are presented in U.S. dollars (“USD”), which is the Company’s presentation currency. Items included in the financial statements of each of the Company’s subsidiaries are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transaction. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities not denominated in the functional currency of an entity are recognized in the statement of operations and deficit. Assets and liabilities of entities with functional currencies other than U.S. dollars are translated into the presentation currency at the year end rates of exchange, and the results of their operations are translated at average rates of exchange for the year. The resulting translation adjustments are included in accumulated other comprehensive loss in shareholders’ equity. Additionally, foreign exchange gains and losses related to certain intercompany loans that are permanent in nature are included in accumulated other comprehensive loss. Elements of equity are translated at historical rates.
Financial Instruments	Financial Instruments Financial assets held with an objective to hold assets in order to collect contractual cash flows which arise on specified dates that are solely principal and interest are measured at amortised cost using the effective interest method. Debt investments held with an objective to hold both assets in order to collect contractual cash flows which arise on specified dates that are solely principal and interest as well as selling the asset on the basis of fair value are measured at FVTOCI. All other financial assets are classified and measured at fair value through profit or loss (“FVTPL”). Financial liabilities are classified as either FVTPL or other financial liabilities, and the portion of the change in fair value that relates to the Company’s credit risk is presented in other comprehensive loss. Instruments classified as FVTPL are measured at fair value with unrealized gains and losses recognized in net loss. Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Transaction costs that are directly attributable to the acquisition or issuance of financial assets and financial liabilities, other than financial assets and financial liabilities classified as FVTPL, are added to or deducted from the fair value on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities classified as FVTPL are recognized immediately in consolidated net loss. Financial assets The Company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and it does not retain control of the financial asset. Any interest in transferred financial assets that is created or retained by the Company is recognized as a separate asset or liability. Financial liabilities A financial liability is derecognized from the balance sheet when it is extinguished, that is, when the obligation specified in the contract is either discharged, cancelled or expires. Where there has been an exchange between an existing borrower and lender of debt instruments with substantially different terms, or there has been a substantial modification of the terms of an existing financial liability, this transaction is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. A gain or loss from extinguishment of the original financial liability is recognized in profit or loss. The Company’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, contract liabilities and covid-19 government support loans. POET TECHNOLOGIES INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars) 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) The following table outlines the classification of financial instruments under IFRS 9: SCHEDULE OF CLASSIFICATION OF FINANCIAL INSTRUMENTS Financial Assets Cash and cash equivalents Amortized cost Accounts receivable Amortized cost Financial Liabilities Accounts payable and accrued liabilities Amortized cost Contract liabilities Amortized cost Covid-19 government support loans Amortized cost Convertible debentures are accounted for as a compound financial instrument with a debt component and a separate equity component. The debt component of these compound financial instruments is measured at fair value on initial recognition by discounting the stream of future interest and principal payments at the rate of interest prevailing at the date of issue for instruments of similar term and risk. The debt component is subsequently deducted from the total carrying value of the compound instrument to derive the equity component. The debt component is subsequently measured at amortized cost using the effective interest rate method. Interest expense based on the coupon rate of the debenture and the accretion of the liability component to the amount that will be payable on redemption are recognized through profit or loss as a finance cost.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents consist of cash in current accounts of $ 1,168,483 1,981,765 3,307,995 7,248,080 4% 4.2%
Property and equipment	Property and equipment Property and equipment are recorded at cost. Depreciation is calculated based on the estimated useful life of the asset using the following method and useful lives: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED LIFE Machinery and equipment Straight Line, 5 Leasehold improvements Straight Line, 5 Office equipment Straight Line, 3 5
Patents and licenses	Patents and licenses Patents and licenses are recorded at cost and amortized on a straight line basis over 12
Revenue recognition	Revenue recognition Revenue is measured based on the consideration specified in a contract with a customer and excludes amounts collected on behalf of third parties. The Company recognizes revenue when it transfers control over a product or service to a customer. Sale of goods Revenue from the sale of goods is recognized, net of discounts and customer rebates, at the point in time the transfer of control of the related products has taken place as specified in the sales contract and collectability is reasonably assured. POET TECHNOLOGIES INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars) 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Service revenue The Company provides contract services, primarily in the form of non-recurring revenue (“NRE”) where control is passed to the customer over time. The contracts generally provide agreed upon milestones for customer payment which include but are not limited to the delivery of sample products, design reports and test reports. The customer makes payment when it has approved the delivery of the milestone. The Company must determine if the contract is made up of a series of independent performance obligations or a single performance obligation. Where NRE contracts contain multiple performance obligations for which a standalone transaction price can be assessed, revenue is recognized as each performance obligation is satisfied. Where NRE contracts contain a single performance obligation to be settled over time, revenue is recognized progressively based on the output method.
Other income	Other income Interest income Interest income on cash and cash equivalents and short-term investments is recognized as earned using the effective interest method.
Wage subsidies	Wage subsidies Wages subsidies received from the Singaporean government are netted against payroll costs on the consolidated statements of operations and deficit.
Government Grants	Government Grants Loans received exclusively from governmental agencies to support the Company throughout the COVID-19 pandemic qualify to be forgiven if certain conditions are met. Forgiveness of COVID-19 related loans will be recognized as other income on the consolidated statements of operations and deficit.
Stock-based compensation	Stock-based compensation Stock options and warrants awarded to non employees are measured using the fair value of the goods or services received unless that fair value cannot be estimated reliably, in which case measurement is based on the fair value of the stock options. Stock options and warrants awarded to employees are accounted for using the fair value method. The fair value of such stock options and warrants granted is recognized as an expense on a proportionate basis consistent with the vesting features of each tranche of the grant. The fair value is calculated using the Black-Scholes option pricing model with assumptions applicable at the date of grant.
Loss per share	Loss per share Basic loss per share, net of taxes is calculated by dividing net loss by the weighted average number of common shares outstanding during the year. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding during the period after giving effect to potentially dilutive financial instruments. The dilutive effect of stock options and warrants is determined using the treasury stock method.
Joint Venture	Joint Venture A joint arrangement is an arrangement among two or more parties where the parties are bound by a contractual arrangement and the contractual arrangement gives the parties joint control of the arrangement. A joint venture is a form of joint arrangement where an entity is independently formed and the parties jointly have rights to the net assets of the arrangement and therefore account for their interests under the equity method.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
SCHEDULE OF CLASSIFICATION OF FINANCIAL INSTRUMENTS	The following table outlines the classification of financial instruments under IFRS 9: SCHEDULE OF CLASSIFICATION OF FINANCIAL INSTRUMENTS Financial Assets Cash and cash equivalents Amortized cost Accounts receivable Amortized cost Financial Liabilities Accounts payable and accrued liabilities Amortized cost Contract liabilities Amortized cost Covid-19 government support loans Amortized cost
SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED LIFE	Property and equipment are recorded at cost. Depreciation is calculated based on the estimated useful life of the asset using the following method and useful lives: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED LIFE Machinery and equipment Straight Line, 5 Leasehold improvements Straight Line, 5 Office equipment Straight Line, 3 5

ACCOUNTS RECEIVABLE AND CONTR_2

ACCOUNTS RECEIVABLE AND CONTRACT LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2023
Accounts Receivable And Contract Liabilities
SCHEDULE OF REVENUE CONTRACT BALANCES	Revenue Contract Balances SCHEDULE OF REVENUE CONTRACT BALANCES Contract Receivables Liabilities Opening balance, January 1, 2023 $ 62,842 $ (274,192 ) Changes due to payment, fulfillment of performance obligations or revenues recognized (62,842 ) 157,500 Effect of changes in foreign exchange rates - 11,429 Balance, September 30, 2023 $ - $ (105,263 )

PREPAIDS AND OTHER CURRENT AS_2

PREPAIDS AND OTHER CURRENT ASSETS (Tables)	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
SCHEDULE OF PRREPAIDS AND OTHER CURRENT ASSETS	The following table reflects the details of prepaids and other current assets: SCHEDULE OF PRREPAIDS AND OTHER CURRENT ASSETS September 30, December 31, 2023 2022 Sales tax recoverable and other current assets $ 78,005 $ 128,321 Prepaid expenses 356,814 147,186 Equipment deposit 28,103 - Prepaids and other current assets $ 462,922 275,507

JOINT VENTURE (Tables)

JOINT VENTURE (Tables)	9 Months Ended
	Sep. 30, 2023
Joint Venture
SCHEDULE OF FINANCIAL INFORMATION OF JOINT VENTURE	Summarized financial information of the joint venture is as follows: SCHEDULE OF FINANCIAL INFORMATION OF JOINT VENTURE September 30, December 31, 2023 2022 Current assets $ 1,315,146 1,951,654 Intangible assets 16,199,173 18,708,065 Liabilities (154,720 ) (180,897 ) Owners Equity (17,359,599 ) (20,478,822 ) Net loss for the nine months ended September 30, 2023 and 2022 $ 2,914,956 $ 1,329,525

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	SCHEDULE OF PROPERTY AND EQUIPMENT Equipment not Leasehold Machinery and Office in service improvements equipment equipment Total Cost Balance, January 1, 2022 $ - $ 117,115 $ 4,830,020 $ 183,269 $ 5,130,404 Additions, net of returns 1,902,713 - 1,087,414 21,435 3,011,562 Reclassification (141,702 ) - 162,917 (21,215 ) - Effect of changes in foreign exchange rates 54,898 6,544 11,270 (5,586 ) 67,126 Balance, December 31, 2022 1,815,909 123,659 6,091,621 177,903 8,209,092 Property and equipment, cost, Beginning balance 1,815,909 123,659 6,091,621 177,903 8,209,092 Additions 206,378 - 913,731 12,405 1,132,514 Reclassification (2,016,605 ) - 2,016,605 - - Effect of changes in foreign exchange rates, net (5,682 ) (883 ) (99,377 ) 4,261 (101,681 ) Balance, September 30, 2023 - 122,776 8,922,580 194,569 9,239,925 Property and equipment, cost, Ending balance - 122,776 8,922,580 194,569 9,239,925 Accumulated Depreciation Balance, January 1, 2022 - 29,526 1,930,726 105,918 2,066,170 Depreciation - 24,079 1,000,085 30,100 1,054,264 Effect on changes in foreign exchange rates - 2,529 27,727 (12,105 ) 18,151 Balance, December 31, 2022 - 56,134 2,958,538 123,913 3,138,585 Property and equipment, accumulated depreciation, Beginning balance - 56,134 2,958,538 123,913 3,138,585 Depreciation for the period - 18,544 1,178,524 24,022 1,221,090 Balance, September 30, 2023 - 74,678 4,137,062 147,935 4,359,675 Property and equipment, accumulated depreciation, Ending balance - 74,678 4,137,062 147,935 4,359,675 Carrying Amounts At December 31, 2022 $ 1,815,909 $ 67,525 $ 3,133,083 $ 53,990 $ 5,070,507 Property and equipment, carrying amounts, Beginning balance $ 1,815,909 $ 67,525 $ 3,133,083 $ 53,990 $ 5,070,507 At September 30, 2023 $ - $ 48,098 $ 4,785,518 $ 46,634 $ 4,880,250 Property and equipment, carrying amounts, Ending balance 48,098 4,785,518 46,634 4,880,250

PATENTS AND LICENSES (Tables)

PATENTS AND LICENSES (Tables)	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
SCHEDULE OF PATENTS AND LICENSES	SCHEDULE OF PATENTS AND LICENSES Cost Balance, January 1, 2022 $ 996,461 Additions 62,475 Balance, December 31, 2022 1,058,936 Patents and licenses, cost, beginning 1,058,936 Additions 79,110 Balance, September 30, 2023 1,138,046 Patents and licenses, cost, ending 1,138,046 Accumulated Depreciation Balance, January 1, 2022 467,985 Amortization 80,246 Balance, December 31, 2022 548,231 Patents and licenses, accumulated amortization, beginning 548,231 Amortization during the period 66,058 Balance, September 30, 2023 614,289 Patents and licenses, accumulated amortization, ending 614,289 Carrying Amounts At December 31, 2022 $ 510,705 Patents and licenses, carrying amounts, beginning $ 510,705 At September 30, 2023 $ 523,757 Patents and licenses, carrying amounts, ending 523,757

RIGHT OF USE ASSET AND LEASE _2

RIGHT OF USE ASSET AND LEASE LIABILITY (Tables)	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
SCHEDULE OF RIGHT OF USE ASSET AND LEASE LIABILITY	SCHEDULE OF RIGHT OF USE ASSET AND LEASE LIABILITY Right of use asset Building Cost Balance, January 1, 2022 $ 649,110 Lease modification 81,542 Balance, December 31, 2022 730,652 Right of use asset, Cost, Beginning balance 730,652 Additions 260,352 Balance, September 30, 2023 991,004 Right of use asset, Cost, Ending balance 991,004 Accumulated Amortization Balance, January 1, 2022 322,220 Amortization 158,648 Effect of changes in foreign exchange rates 8,737 Balance, December 31, 2022 489,605 Right of use asset, Accumulated Amortization, Beginning balance 489,605 Amortization during the period 129,122 Effect of changes in foreign exchange rates, net 6,596 Balance, September 30, 2023 625,323 Right of use asset, Accumulated Amortization, Ending balance 625,323 Carrying Amounts At December 31, 2022 $ 241,047 Right of use asset, Carrying Amounts, Beginning balance $ 241,047 At September 30, 2023 $ 365,681 Right of use asset, Carrying Amounts, Ending balance 365,681 Lease liability Balance, January 1, 2022 $ 359,348 Interest expense 49,738 Lease payments (204,518 ) Lease modification 81,542 Effect of changes in foreign exchange rates (6,847 ) Balance, December 31, 2022 279,263 Lease liability, Beginning balance 279,263 Additions 260,352 Interest expense (1) 40,067 Lease payments (172,820 ) Effect of changes in foreign exchange rates, net (7,403 ) Balance, September 30, 2023 $ 399,459 Lease liability, Ending balance 399,459 (1) The Company paid $ 16,568

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES September 30, December 31, 2023 2022 Trade payable $ 848,075 $ 2,723,531 Payroll related liabilities 449,465 452,751 Accrued liabilities 55,668 186,148 Total accounts payable and accrued liabilities $ 1,353,208 $ 3,362,430 POET TECHNOLOGIES INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars)

SHARE CAPITAL (Tables)

SHARE CAPITAL (Tables)	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
SCHEDULE OF COMMON SHARES ISSUED	SCHEDULE OF COMMON SHARES ISSUED Number of Amount Balance, January 1, 2022 36,494,228 $ 147,729,846 Shares issued to settle accounts payable 5,422 40,029 Funds from common shares issued on private placement 1,126,635 3,184,332 Fair value of warrants issued on private placement - (656,734 ) Share issue costs - (247,892 ) Funds from the exercise of stock options 143,437 418,845 Fair value of stock options exercised - 374,129 Funds from the exercise of warrants and compensation warrants 72,500 284,437 Fair value of warrants and compensation warrants exercised - 79,547 Adjustment for 10 for 1 share consolidation (272 ) - Balance, December 31, 2022 37,841,950 151,206,539 Funds from the exercise of stock options 245,606 612,310 Fair value of stock options exercised - 538,168 Funds from the exercise of warrants 2,364,066 7,767,067 Fair value of warrants exercised - 4,418,783 Funds from Common shares issued through ATM financing 227,673 983,194 Share issue costs - (320,712 ) Balance, September 30, 2023 40,679,295 $ 165,205,349

WARRANTS AND COMPENSATION OPT_2

WARRANTS AND COMPENSATION OPTIONS (Tables)	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
SCHEDULE OF WARRANTS AND COMPENSATION OPTIONS	The following table reflects the continuity of warrants and compensation options: SCHEDULE OF WARRANTS AND COMPENSATION OPTIONS Historical Number of Average Exercise Price Warrants/ Compensation options Historical Fair value Balance, January 1, 2022 $ 7.10 3,021,353 $ 5,328,455 Fair value of warrant issued on private placement 1.17 563,318 656,734 Historical fair value assigned to warrants exercised 3.90 (72,500 ) (79,547 ) Balance, December 31, 2022 6.15 3,512,171 5,905,642 Historical fair value assigned to warrants exercised 3.27 (2,364,066 ) (4,418,783 ) Historical fair value of warrants expired 4.50 (584,787 ) (816,744 ) Balance, September 30, 2023 $ 3.64 563,318 $ 670,115

STOCK OPTIONS AND CONTRIBUTED_2

STOCK OPTIONS AND CONTRIBUTED SURPLUS (Tables)	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
SCHEDULE OF STOCK OPTIONS OUTSTANDING	Stock option transactions and the number of stock options outstanding were as follows: SCHEDULE OF STOCK OPTIONS OUTSTANDING Number of Historical Balance, January 1, 2022 4,959,617 $ 4.40 Expired/cancelled (117,438 ) 6.02 Exercised (143,437 ) 2.85 Granted 2,043,083 3.32 Balance, December 31, 2022 6,741,825 4.10 Expired/cancelled (182,750 ) 4.66 Exercised (245,606 ) 2.49 Granted 1,002,170 4.11 Balance, September 30, 2023 7,315,639 $ 4.14
SCHEDULE OF STOCK OPTIONS ASSUMPTIONS	The stock options granted were valued using the Black-Scholes option pricing model using the following assumptions: SCHEDULE OF STOCK OPTIONS ASSUMPTIONS Nine Months Ended September 30, 2023 2022 Weighted average exercise price $ 4.11 $ 6.39 Weighted average risk-free interest rate 2.88 3.48 % 1.80 3.5 % Weighted average dividend yield 0 % 0 % Weighted average volatility 82.45 % 84.74 % Weighted average estimated life 10 10 Weighted average share price $ 4.11 $ 6.39 Share price on the various grant dates: $ 4.05 4.63 $ 4.37 6.86 Weighted average fair value $ 3.42 $ 5.41
SCHEDULE OF WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE AND WEIGHTED AVERAGE EXERCISE PRICE OF OPTIONS	The weighted average remaining contractual life and weighted average exercise price of options outstanding and of options exercisable as at September 30, 2023 are as follows: SCHEDULE OF WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE AND WEIGHTED AVERAGE EXERCISE PRICE OF OPTIONS Options Outstanding Options Exercisable Exercise Range Number Historical Weighted Average Weighted Average Remaining Number Historical $ 0.82 1.93 7,000 $ 1.91 4.84 7,000 $ 1.91 $ 1.93 2.76 1,873,823 $ 2.38 6.42 1,267,829 $ 2.28 $ 2.76 8.84 5,434,816 $ 4.31 7.46 3,208,513 $ 4.21 7,315,639 $ 3.81 7.20 4,483,342 $ 3.66

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
SCHEDULE OF INCOME (LOSS) PER SHARE	SCHEDULE OF INCOME (LOSS) PER SHARE 2023 2022 2023 2022 Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Numerator Net loss $ (5,136,441 ) $ (4,041,298 ) $ (14,796,351 ) $ (14,756,739 ) Denominator Weighted average number of common shares outstanding - basic and diluted 40,565,912 36,672,390 39,716,526 36,589,778 Basic and diluted loss per share $ (0.13 ) $ (0.11 ) $ (0.37 ) $ (0.40 )

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
SCHEDULE OF REMAINING ANNUAL RENTAL PAYMENTS LEASE	Remaining minimum annual rental payments to the lease expiration dates are as follows: SCHEDULE OF REMAINING ANNUAL RENTAL PAYMENTS LEASE October 1, 2023 to December 31, 2023 $ 66,019 2024 and beyond 457,230 $ 523,249

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
SCHEDULE OF COMPENSATION TO KEY MANAGEMENT PERSONNEL	Compensation to key management personnel were as follows: SCHEDULE OF COMPENSATION TO KEY MANAGEMENT PERSONNEL Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Salaries $ 499,160 $ 504,099 $ 1,505,341 $ 1,472,296 Share-based payments ( 1 ) 493,952 351,751 1,386,341 1,223,152 Total $ 993,112 $ 855,850 $ 2,891,682 $ 2,695,448 (1) Share-based payments are the fair value of options granted to key management personnel and expensed during the various periods as calculated using the Black-Scholes model.

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2023
SCHEDULE OF GEOGRAPHICAL INFORMATION	On a consolidated basis, the Company operates geographically in China and Singapore (collectively “Asia”), the United States and Canada. Geographical information is as follows: SCHEDULE OF GEOGRAPHICAL INFORMATION 2023 As of September 30, Asia US Canada Consolidated Current assets $ 165,961 $ 417,624 $ 4,355,815 $ 4,939,400 Property and equipment 4,300,857 579,393 - 4,880,250 Patents and licenses - 523,757 - 523,757 Right of use assets 242,168 123,513 - 365,681 Total Assets $ 4,708,986 $ 1,644,287 $ 4,355,815 $ 10,709,088 For the Nine Months Ended September 30, Asia US Canada Consolidated Revenue $ 358,226 $ - $ - $ 358,226 Selling, marketing and administration $ (2,025,536 ) $ (4,542,054 ) $ (1,205,432 ) $ (7,773,022 ) Research and development (4,646,713 ) (2,739,509 ) (119,641 ) (7,505,863 ) Interest expense (20,243 ) (36,392 ) - (56,635 ) Share of loss in joint venture (527,857 ) - - (527,857 ) Gain from contribution of IP to joint venture 527,857 - - 527,857 Other income, including Interest - - 180,943 180,943 Net loss $ (6,334,266 ) $ (7,317,955 ) $ (1,144,130 ) $ (14,796,351 ) As of December 31, Asia US Canada Consolidated 2022 As of December 31, Asia US Canada Consolidated Current assets $ 664,658 $ 133,501 $ 8,770,035 $ 9,568,194 Property and equipment 4,496,734 573,773 - 5,070,507 Patents and licenses - 510,705 - 510,705 Right of use assets 55,775 185,272 - 241,047 Total Assets $ 5,217,167 $ 1,403,251 $ 8,770,035 $ 15,390,453 POET TECHNOLOGIES INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Expressed in US Dollars) 17. SEGMENT INFORMATION (continued) For the Nine Months Ended September 30, Asia US Canada Consolidated Revenue $ 353,189 $ - $ - $ 353,189 Selling, marketing and administration $ (1,549,628 ) $ (4,280,844 ) $ (1,074,149 ) $ (6,904,621 ) Research and development (3,992,505 ) (3,099,397 ) (135,470 ) (7,227,372 ) Interest (14,429 ) (23,699 ) - (38,128 ) Share of loss in joint venture (1,555,650 ) - - (1,555,650 ) Gain from contribution of IP to joint venture 496,115 - - 496,115 Other income, including interest - - 119,728 119,728 Net loss $ (6,262,908 ) $ (7,403,940 ) $ (1,089,891 ) $ (14,756,739 )

FINANCIAL INSTRUMENTS AND RIS_2

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
SCHEDULE OF CLASSIFIED FINANCIAL ASSETS AND LIABILITIES	The Company has classified financial assets and (liabilities) as follows: SCHEDULE OF CLASSIFIED FINANCIAL ASSETS AND LIABILITIES September 30, December 31, 2023 2022 Cash and cash equivalents, measured at amortized cost: Cash and cash equivalents $ 4,476,478 $ 9,229,845 Receivables, measured at amortized cost: Accounts receivable $ - $ 62,842 Other liabilities, measured at amortized cost: Accounts payable and accrued liabilities $ (1,353,208 ) $ (3,362,430 ) Covid-19 government support loans $ (29,428 ) $ (29,520 ) Contract liabilities $ (105,263 ) $ (274,192 )

CAPITAL MANAGEMENT (Tables)

CAPITAL MANAGEMENT (Tables)	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
SCHEDULE OF COMPONENTS OF CAPITAL	In the management of capital, the Company includes shareholders’ equity (excluding accumulated other comprehensive loss and deficit) and cash and cash equivalents and short-term investments. The components of capital on September 30, 2023 were: SCHEDULE OF COMPONENTS OF CAPITAL Cash and cash equivalents and short-term investments $ 4,476,478 Shareholders’ equity $ 220,322,204

EXPENSES (Tables)

EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
SCHEDULE OF EXPENSES BY NATURE	Research and development costs can be analysed as follows: SCHEDULE OF EXPENSES BY NATURE 2023 2022 2023 2022 Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Wages and benefits $ 1,074,549 $ 1,042,347 $ 3,221,450 $ 2,990,224 Subcontract fees 314,296 400,475 1,632,010 1,720,487 Stock-based compensation 406,536 477,224 1,109,171 1,280,702 Supplies 654,419 441,945 1,543,232 1,235,959 Research and development costs $ 2,449,800 $ 2,361,991 $ 7,505,863 $ 7,227,372 Selling, marketing and administration costs can be analysed as follows: Stock-based compensation $ 845,112 $ 403,572 $ 2,042,185 $ 1,567,196 Wages and benefits 640,241 646,349 1,973,231 1,983,180 General expenses 387,183 435,990 1,375,911 1,558,810 Professional fees 273,905 203,778 842,403 743,075 Depreciation and amortization 508,484 336,446 1,416,271 952,141 Rent and facility costs 42,274 48,569 123,021 100,219 Selling, marketing and administration costs $ 2,697,199 $ 2,074,704 $ 7,773,022 $ 6,904,621

SCHEDULE OF CLASSIFICATION OF F

SCHEDULE OF CLASSIFICATION OF FINANCIAL INSTRUMENTS (Details)	9 Months Ended
	Sep. 30, 2023
Notes and other explanatory information [abstract]
Financial Assets, Cash and cash equivalents	Amortized cost
Financial Assets, Accounts receivable	Amortized cost
Financial Assets, Accounts payable and accrued liabilities	Amortized cost
Financial Assets, Contract liabilities	Amortized cost
Financial Assets, Covid-19 government support loans	Amortized cost

DESCRIPTION OF BUSINESS (Detail

DESCRIPTION OF BUSINESS (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021
Notes and other explanatory information [abstract]
Accumulated losses	$ (208,820,011)	$ (203,683,570)	$ (194,023,660)	$ (187,743,709)	$ (183,702,411)	$ (172,986,970)
Working capital	3,284,450
Cash flows from operations	12,486,310
Gross funding from private placement	$ 983,194

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED LIFE (Details)	9 Months Ended
	Sep. 30, 2023
Machinery [member]
IfrsStatementLineItems [Line Items]
Estimated useful life of asset	5 years
Leasehold improvements [member]
IfrsStatementLineItems [Line Items]
Estimated useful life of asset	5 years
Office equipment [member] | Bottom of range [member]
IfrsStatementLineItems [Line Items]
Estimated useful life of asset	3 years
Office equipment [member] | Top of range [member]
IfrsStatementLineItems [Line Items]
Estimated useful life of asset	5 years

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
IfrsStatementLineItems [Line Items]
Cash	$ 1,168,483	$ 1,981,765
Patents and Licenses [member]
IfrsStatementLineItems [Line Items]
Useful life, intangible assets	12 years
US and Canadian Term Deposits [Member]
IfrsStatementLineItems [Line Items]
Current investments	$ 3,307,995	$ 7,248,080
US and Canadian Term Deposits [Member] | Bottom of range [member]
IfrsStatementLineItems [Line Items]
Investment interest rate range	4%
US and Canadian Term Deposits [Member] | Top of range [member]
IfrsStatementLineItems [Line Items]
Investment interest rate range	4.20%

SCHEDULE OF REVENUE CONTRACT BA

SCHEDULE OF REVENUE CONTRACT BALANCES (Details)	9 Months Ended
	Sep. 30, 2023 USD ($)
Accounts Receivable And Contract Liabilities
Balance, receivables	$ 62,842
Balance, liabilities	(274,192)
Changes due to payment, fulfillment of performance obligations or revenues recognized, receivables	(62,842)
Changes due to payment, fulfillment of performance obligations or revenues recognized, liabilities	157,500
Effect of changes in foreign exchange rates, receivables
Effect of changes in foreign exchange rates, liabilities	11,429
Balance, receivables
Balance, liabilities	$ (105,263)

SCHEDULE OF PRREPAIDS AND OTHER

SCHEDULE OF PRREPAIDS AND OTHER CURRENT ASSETS (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Notes and other explanatory information [abstract]
Sales tax recoverable and other current assets	$ 78,005	$ 128,321
Prepaid expenses	356,814	147,186
Equipment deposit	28,103
Prepaids and other current assets	$ 462,922	$ 275,507

SCHEDULE OF FINANCIAL INFORMATI

SCHEDULE OF FINANCIAL INFORMATION OF JOINT VENTURE (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
IfrsStatementLineItems [Line Items]
Current assets	$ 4,939,400	$ 9,568,194
Liabilities	(1,887,358)	(3,945,405)
Joint ventures [member]
IfrsStatementLineItems [Line Items]
Current assets	1,315,146	1,951,654
Intangible assets	16,199,173	18,708,065
Liabilities	(154,720)	(180,897)
Owners Equity	(17,359,599)	(20,478,822)
Net loss	$ 2,914,956	$ 1,329,525

JOINT VENTURE (Details Narrativ

JOINT VENTURE (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Super Photonics Xiamen Co Ltd [Member]
IfrsStatementLineItems [Line Items]
Percentage of weighted average net operating loss	79.90%
Net operating loss	$ (2,329,103)
Net operating loss recognized	(527,857)
Joint ventures [member]
IfrsStatementLineItems [Line Items]
Net operating loss	2,914,956	$ 1,329,525
Joint ventures [member] | Super Photonics Xiamen Co Ltd [Member]
IfrsStatementLineItems [Line Items]
Amount of investment in joint venture	22,500,000
Unrecognized gain loss on joint venture	4,868,225
Gain on joint venture	$ 17,631,775
Proportion of ownership interest in joint operation	78.40%
Joint ventures [member] | Sanan I C [Member]
IfrsStatementLineItems [Line Items]
Proportion of ownership interest in joint operation	21.60%
Super Photonics Xiamen Co Ltd [Member]
IfrsStatementLineItems [Line Items]
Percentage of weighted average net operating loss		87.90%
Net operating loss		$ (1,555,650)

SCHEDULE OF PROPERTY AND EQUI_2

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
IfrsStatementLineItems [Line Items]
Property and equipment, cost, Beginning balance	$ 8,209,092	$ 5,130,404
Additions	1,132,514	3,011,562
Reclassification
Effect of changes in foreign exchange rates, net	(101,681)	67,126
Property and equipment, cost, Ending balance	9,239,925	8,209,092
Property and equipment, accumulated depreciation, Beginning balance	3,138,585	2,066,170
Depreciation for the period	1,221,090	1,054,264
Effect on changes in foreign exchange rates		18,151
Property and equipment, accumulated depreciation, Ending balance	4,359,675	3,138,585
Property and equipment, carrying amounts, Beginning balance	5,070,507
Property and equipment, carrying amounts, Ending balance	4,880,250	5,070,507
Equipment not ready for use [Member]
IfrsStatementLineItems [Line Items]
Property and equipment, cost, Beginning balance	1,815,909
Additions	206,378	1,902,713
Reclassification	(2,016,605)	(141,702)
Effect of changes in foreign exchange rates, net	(5,682)	54,898
Property and equipment, cost, Ending balance		1,815,909
Property and equipment, accumulated depreciation, Beginning balance
Depreciation for the period
Effect on changes in foreign exchange rates
Property and equipment, accumulated depreciation, Ending balance
Property and equipment, carrying amounts, Beginning balance	1,815,909
Property and equipment, carrying amounts, Ending balance		1,815,909
Leasehold improvements [member]
IfrsStatementLineItems [Line Items]
Property and equipment, cost, Beginning balance	123,659	117,115
Additions
Reclassification
Effect of changes in foreign exchange rates, net	(883)	6,544
Property and equipment, cost, Ending balance	122,776	123,659
Property and equipment, accumulated depreciation, Beginning balance	56,134	29,526
Depreciation for the period	18,544	24,079
Effect on changes in foreign exchange rates		2,529
Property and equipment, accumulated depreciation, Ending balance	74,678	56,134
Property and equipment, carrying amounts, Beginning balance	67,525
Property and equipment, carrying amounts, Ending balance	48,098	67,525
Machinery and equipment [Member]
IfrsStatementLineItems [Line Items]
Property and equipment, cost, Beginning balance	6,091,621	4,830,020
Additions	913,731	1,087,414
Reclassification	2,016,605	162,917
Effect of changes in foreign exchange rates, net	(99,377)	11,270
Property and equipment, cost, Ending balance	8,922,580	6,091,621
Property and equipment, accumulated depreciation, Beginning balance	2,958,538	1,930,726
Depreciation for the period	1,178,524	1,000,085
Effect on changes in foreign exchange rates		27,727
Property and equipment, accumulated depreciation, Ending balance	4,137,062	2,958,538
Property and equipment, carrying amounts, Beginning balance	3,133,083
Property and equipment, carrying amounts, Ending balance	4,785,518	3,133,083
Office equipment [member]
IfrsStatementLineItems [Line Items]
Property and equipment, cost, Beginning balance	177,903	183,269
Additions	12,405	21,435
Reclassification		(21,215)
Effect of changes in foreign exchange rates, net	4,261	(5,586)
Property and equipment, cost, Ending balance	194,569	177,903
Property and equipment, accumulated depreciation, Beginning balance	123,913	105,918
Depreciation for the period	24,022	30,100
Effect on changes in foreign exchange rates		(12,105)
Property and equipment, accumulated depreciation, Ending balance	147,935	123,913
Property and equipment, carrying amounts, Beginning balance	53,990
Property and equipment, carrying amounts, Ending balance	$ 46,634	$ 53,990

SCHEDULE OF PATENTS AND LICENSE

SCHEDULE OF PATENTS AND LICENSES (Details) - Patents and Licenses [member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
IfrsStatementLineItems [Line Items]
Patents and licenses, cost, beginning	$ 1,058,936	$ 996,461
Additions	79,110	62,475
Patents and licenses, cost, ending	1,138,046	1,058,936
Patents and licenses, accumulated amortization, beginning	548,231	467,985
Amortization during the period	66,058	80,246
Patents and licenses, accumulated amortization, ending	614,289	548,231
Patents and licenses, carrying amounts, beginning	510,705
Patents and licenses, carrying amounts, ending	$ 523,757	$ 510,705

SCHEDULE OF RIGHT OF USE ASSET

SCHEDULE OF RIGHT OF USE ASSET AND LEASE LIABILITY (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2023		Dec. 31, 2022
Notes and other explanatory information [abstract]
Right of use asset, Cost, Beginning balance	$ 730,652		$ 649,110
Lease modification			81,542
Additions	260,352
Right of use asset, Cost, Ending balance	991,004		730,652
Right of use asset, Accumulated Amortization, Beginning balance	489,605		322,220
Amortization during the period	129,122		158,648
Effect of changes in foreign exchange rates, net	6,596		8,737
Right of use asset, Accumulated Amortization, Ending balance	625,323		489,605
Right of use asset, Carrying Amounts, Beginning balance	241,047
Right of use asset, Carrying Amounts, Ending balance	365,681		241,047
Lease liability, Beginning balance	279,263		359,348
Interest expense	40,067	[1]	49,738
Lease payments	(172,820)		(204,518)
Lease modification			81,542
Effect of changes in foreign exchange rates, net	(7,403)		(6,847)
Additions	260,352
Lease liability, Ending balance	$ 399,459		$ 279,263
[1]The Company paid $ 16,568

SCHEDULE OF RIGHT OF USE ASSE_2

SCHEDULE OF RIGHT OF USE ASSET AND LEASE LIABILITY (Details) (Parenthetical)	9 Months Ended
	Sep. 30, 2023 USD ($)
Notes and other explanatory information [abstract]
Other finance costs	$ 16,568

SCHEDULE OF ACCOUNTS PAYABLE AN

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Notes and other explanatory information [abstract]
Trade payable	$ 848,075	$ 2,723,531
Payroll related liabilities	449,465	452,751
Accrued liabilities	55,668	186,148
Total accounts payable and accrued liabilities	$ 1,353,208	$ 3,362,430

RIGHT OF USE ASSET AND LEASE _3

RIGHT OF USE ASSET AND LEASE LIABILITY (Details Narrative)	Sep. 30, 2023
Notes and other explanatory information [abstract]
Incremental borrowing rate	12%

COVID-19 GOVERNMENT SUPPORT L_2

COVID-19 GOVERNMENT SUPPORT LOANS (Details Narrative)	Apr. 15, 2020 USD ($)	Apr. 09, 2020 USD ($)	Dec. 31, 2022 USD ($)	Apr. 09, 2020 CAD ($)
Canada Emergency Business Account [Member]
IfrsStatementLineItems [Line Items]
Canada emergency business account description	the Company received a loan in the amount of $29,428 (2022 - $29,520) through the CEBA. If the loan has not been repaid by December 31, 2023, the outstanding amount will be automatically extended for an additional two years at 5% interest per annum payable monthly and maturing on December 31, 2025. The Company expects to repay 75% of the amount borrowed prior to December 31, 2023.	the Canadian government launched the Canada Emergency Business Account (“CEBA”) which is intended to support businesses during COVID-19 by providing interest free financing of up to $29,428 (CA$40,000) until December 31, 2023. If 75% of the loan is repaid by December 31, 2023, the loan recipient will be eligible for a loan forgiveness of the remaining 25% of the amount loaned.
Paycheck Protection Program [Member]
IfrsStatementLineItems [Line Items]
Loans received	$ 29,428	$ 29,428	$ 29,520	$ 40,000
Borrowings interest rate	5%

SCHEDULE OF COMMON SHARES ISSUE

SCHEDULE OF COMMON SHARES ISSUED (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Notes and other explanatory information [abstract]
Opening balance, shares	37,841,950	36,494,228
Opening balance, value	$ 151,206,539	$ 147,729,846
Shares issued to settle accounts payable, shares		5,422
Shares issued to settle accounts payable, value		$ 40,029
Funds from Common shares issued on privale placement, shares		1,126,635
Funds from Common shares issued on privale placement, value		$ 3,184,332
Fair value of warrants issued on private placement, shares
Fair value of warrants issued on private placement, value		$ (656,734)
Share issue costs, shares
Share issue costs, value	$ (320,712)	$ (247,892)
Funds from the exercise of stock options, shares	245,606	143,437
Funds from the exercise of stock options, value	$ 612,310	$ 418,845
Fair value of stock options exercised, shares
Fair value of stock options exercised , value	$ 538,168	$ 374,129
Funds from the exercise of warrants, shares	2,364,066	72,500
Funds from the exercise of warrants, value	$ 7,767,067	$ 284,437
Fair value of exercised warrants, shares
Fair value of exercised warrants, value	$ 4,418,783	$ 79,547
Adjustment of share for consolidation, shares		(272)
Adjustment of share for consolidation, value
Funds from Common shares issued through ATM financing, shares	227,673
Funds from Common shares issued through ATM financing, value	$ 983,194
Ending balance, shares	40,679,295	37,841,950
Ending balance, value	$ 165,205,349	$ 151,206,539

SCHEDULE OF WARRANTS AND COMPEN

SCHEDULE OF WARRANTS AND COMPENSATION OPTIONS (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Notes and other explanatory information [abstract]
Warrants and Compensation Options, Historical Average Exercise Price Beginning Balance	$ 6.15	$ 7.10
Warrants and Compensation Options, Number of Warrants/Compensation options Beginning Balance	3,512,171	3,021,353
Warrants and Compensation Options, Historical Fair value Beginning Balance	$ 5,905,642	$ 5,328,455
Fair value of warrant issued on private placement, Historical Average Exercise Price		$ 1.17
Fair value of warrant issued on private placement, Number of Warrants/Compensation options		563,318
Fair value of warrant issued on private placement, Historical Fair value		$ 656,734
Historical fair value assigned to warrants exercised, Historical Average Exercise Price	$ 3.27	$ 3.90
Historical fair value assigned to warrants exercised, Number of Warrants/Compensation options	(2,364,066)	(72,500)
Historical fair value assigned to warrants exercised, Historical Fair value	$ (4,418,783)	$ (79,547)
Historical fair value of warrants expired, Historical Average Exercise Price	$ 4.50
Historical fair value of warrants expired, Number of Warrants/Compensation options	(584,787)
Historical fair value of warrants expired, Historical Fair value	$ (816,744)
Warrants and Compensation Options, Historical Average Exercise Price Ending Balance	$ 3.64	$ 6.15
Warrants and Compensation Options, Number of Warrants/Compensation options Ending Balance	563,318	3,512,171
Warrants and Compensation Options, Historical Fair value Ending Balance	$ 670,115	$ 5,905,642

SHARE CAPITAL (Details Narrativ

SHARE CAPITAL (Details Narrative)	9 Months Ended
	Sep. 30, 2023 USD ($) shares
Notes and other explanatory information [abstract]
Convertible debentures converted value	$ 983,194
Number of shares issued | shares	227,673
Convertible debentures converted value	$ 30,000,000
Percentage of commission	3%
Proceed from issuing shares	$ 29,486
Legal and filing fees	$ 291,226

SCHEDULE OF STOCK OPTIONS OUTST

SCHEDULE OF STOCK OPTIONS OUTSTANDING (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2023 shares $ / shares	Dec. 31, 2022 shares $ / shares
Notes and other explanatory information [abstract]
Number of Options, Outstanding, Beginning Balance | shares	6,741,825	4,959,617
Historical Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 4.10	$ 4.40
Number of Options, Expired/cancelled | shares	(182,750)	(117,438)
Historical Weighted Average Exercise Price, Expired/cancelled | $ / shares	$ 4.66	$ 6.02
Number of Options, Exercised | shares	(245,606)	(143,437)
Historical Weighted Average Exercise Price, Exercised | $ / shares	$ 2.49	$ 2.85
Number of Options, Granted | shares	1,002,170	2,043,083
Historical Weighted Average Exercise Price, Granted | $ / shares	$ 4.11	$ 3.32
Number of Options, Outstanding, Ending Balance | shares	7,315,639	6,741,825
Historical Weighted Average Exercise Price, Ending Balance | $ / shares	$ 4.14	$ 4.10

SCHEDULE OF STOCK OPTIONS ASSUM

SCHEDULE OF STOCK OPTIONS ASSUMPTIONS (Details) - $ / shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
IfrsStatementLineItems [Line Items]
Weighted average exercise price	$ 4.11	$ 6.39
Weighted average dividend yield	0%	0%
Weighted average volatility	82.45%	84.74%
Weighted average estimated life	10 years	10 years
Weighted average share price	$ 4.11	$ 6.39
Weighted average fair value	$ 3.42	$ 5.41
Bottom of range [member]
IfrsStatementLineItems [Line Items]
Weighted average risk-free interest rate	2.88%	1.80%
Share price on the various grant dates	$ 4.05	$ 4.37
Top of range [member]
IfrsStatementLineItems [Line Items]
Weighted average risk-free interest rate	3.48%	3.50%
Share price on the various grant dates	$ 4.63	$ 6.86

SCHEDULE OF WEIGHTED AVERAGE RE

SCHEDULE OF WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE AND WEIGHTED AVERAGE EXERCISE PRICE OF OPTIONS (Details)	9 Months Ended
	Sep. 30, 2023 shares $ / shares	Dec. 31, 2022 shares $ / shares	Dec. 31, 2021 shares $ / shares
IfrsStatementLineItems [Line Items]
Number Outstanding | shares	7,315,639	6,741,825	4,959,617
Historical Weighted Average Exercise Price	$ 4.14	$ 4.10	$ 4.40
Exercise Range One [member]
IfrsStatementLineItems [Line Items]
Number Outstanding | shares	7,000
Historical Weighted Average Exercise Price	$ 1.91
Weighted Average Remaining Remaining Life (years)	4 years 10 months 2 days
Number Exercisable | shares	7,000
Historical Weighted Average Exercise Price	$ 1.91
Exercise Range One [member] | Bottom of range [member]
IfrsStatementLineItems [Line Items]
Exercise Range	0.82
Exercise Range One [member] | Top of range [member]
IfrsStatementLineItems [Line Items]
Exercise Range	$ 1.93
Exercise Range Two [member]
IfrsStatementLineItems [Line Items]
Number Outstanding | shares	1,873,823
Historical Weighted Average Exercise Price	$ 2.38
Weighted Average Remaining Remaining Life (years)	6 years 5 months 1 day
Number Exercisable | shares	1,267,829
Historical Weighted Average Exercise Price	$ 2.28
Exercise Range Two [member] | Bottom of range [member]
IfrsStatementLineItems [Line Items]
Exercise Range	1.93
Exercise Range Two [member] | Top of range [member]
IfrsStatementLineItems [Line Items]
Exercise Range	$ 2.76
Exercise Range Three [member]
IfrsStatementLineItems [Line Items]
Number Outstanding | shares	5,434,816
Historical Weighted Average Exercise Price	$ 4.31
Weighted Average Remaining Remaining Life (years)	7 years 5 months 15 days
Number Exercisable | shares	3,208,513
Historical Weighted Average Exercise Price	$ 4.21
Exercise Range Three [member] | Bottom of range [member]
IfrsStatementLineItems [Line Items]
Exercise Range	2.76
Exercise Range Three [member] | Top of range [member]
IfrsStatementLineItems [Line Items]
Exercise Range	$ 8.84
Options Outstanding [Member]
IfrsStatementLineItems [Line Items]
Number Outstanding | shares	7,315,639
Historical Weighted Average Exercise Price	$ 3.81
Options Exercisable [Member]
IfrsStatementLineItems [Line Items]
Weighted Average Remaining Remaining Life (years)	7 years 2 months 12 days
Number Exercisable | shares	4,483,342
Historical Weighted Average Exercise Price	$ 3.66

SCHEDULE OF INCOME (LOSS) PER S

SCHEDULE OF INCOME (LOSS) PER SHARE (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Notes and other explanatory information [abstract]
Net loss	$ (5,136,441)	$ (4,041,298)	$ (14,796,351)	$ (14,756,739)
Weighted average number of common shares outstanding - basic	40,565,912	36,672,390	39,716,526	36,589,778
Weighted average number of common shares outstanding -diluted	40,565,912	36,672,390	39,716,526	36,589,778
Loss per share - basic	$ (0.13)	$ (0.11)	$ (0.37)	$ (0.40)
Loss per share - diluted	$ (0.13)	$ (0.11)	$ (0.37)	$ (0.40)

SCHEDULE OF REMAINING ANNUAL RE

SCHEDULE OF REMAINING ANNUAL RENTAL PAYMENTS LEASE (Details)	Sep. 30, 2023 USD ($)
IfrsStatementLineItems [Line Items]
Remaining minimum annual rental payments	$ 523,249
October 1, 2023 to December 31, 2023 [Member]
IfrsStatementLineItems [Line Items]
Remaining minimum annual rental payments	66,019
2024 and beyond [member]
IfrsStatementLineItems [Line Items]
Remaining minimum annual rental payments	$ 457,230

SCHEDULE OF COMPENSATION TO KEY

SCHEDULE OF COMPENSATION TO KEY MANAGEMENT PERSONNEL (Details) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Notes and other explanatory information [abstract]
Salaries		$ 499,160	$ 504,099	$ 1,505,341	$ 1,472,296
Share-based payments	[1]	493,952	351,751	1,386,341	1,223,152
Total		$ 993,112	$ 855,850	$ 2,891,682	$ 2,695,448
[1]Share-based payments are the fair value of options granted to key management personnel and expensed during the various periods as calculated using the Black-Scholes model.

STOCK OPTIONS AND CONTRIBUTED_3

STOCK OPTIONS AND CONTRIBUTED SURPLUS (Details Narrative)		9 Months Ended
	Jun. 30, 2023 shares	Sep. 30, 2023 USD ($) $ / shares	Sep. 30, 2022 USD ($) $ / shares
IfrsStatementLineItems [Line Items]
Number of instruments granted in sharebased payment arrangement		1,002,170	242,939
Common shares average price | $ / shares		$ 4.11	$ 6.39
Stock based compensation | $		$ 3,151,356	$ 2,847,898
2021 Plan [member]
IfrsStatementLineItems [Line Items]
Fixed stock option percentage	20%
Number of shares stock option granted | shares	8,056,055
Maximum percentage of issued and outstanding shares percentage	20%

SCHEDULE OF GEOGRAPHICAL INFORM

SCHEDULE OF GEOGRAPHICAL INFORMATION (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
IfrsStatementLineItems [Line Items]
Current assets	$ 4,939,400		$ 4,939,400		$ 9,568,194
Property and equipment	4,880,250		4,880,250		5,070,507
Right of use assets	365,681		365,681		241,047
Total assets	10,709,088		10,709,088		15,390,453
Revenue		$ 232,928	358,226	$ 353,189
Selling, marketing and administration	(2,697,199)	(2,074,704)	(7,773,022)	(6,904,621)
Research and development	(2,449,800)	(2,361,991)	(7,505,863)	(7,227,372)
Interest	(34,890)	(11,707)	(56,635)	(38,128)
Other income, including interest	45,448	57,429	180,943	119,728
Net loss	(5,136,441)	$ (4,041,298)	(14,796,351)	(14,756,739)
Operating segments [member]
IfrsStatementLineItems [Line Items]
Current assets	4,939,400		4,939,400		9,568,194
Property and equipment	4,880,250		4,880,250		5,070,507
Patents and licenses	523,757		523,757		510,705
Right of use assets	365,681		365,681		241,047
Total assets	10,709,088		10,709,088		15,390,453
Revenue			358,226	353,189
Selling, marketing and administration			(7,773,022)	(6,904,621)
Research and development			(7,505,863)	(7,227,372)
Interest			(56,635)	(38,128)
Share of loss in joint venture			(527,857)	(1,555,650)
Gain from contribution of IP to joint venture			527,857	496,115
Other income, including interest			180,943	119,728
Net loss			(14,796,351)	(14,756,739)
Asia [member]
IfrsStatementLineItems [Line Items]
Current assets	165,961		165,961		664,658
Property and equipment	4,300,857		4,300,857		4,496,734
Patents and licenses
Right of use assets	242,168		242,168		55,775
Total assets	4,708,986		4,708,986		5,217,167
Revenue			358,226	353,189
Selling, marketing and administration			(2,025,536)	(1,549,628)
Research and development			(4,646,713)	(3,992,505)
Interest			(20,243)	(14,429)
Share of loss in joint venture			(527,857)	(1,555,650)
Gain from contribution of IP to joint venture			527,857	496,115
Other income, including interest
Net loss			(6,334,266)	(6,262,908)
US [member]
IfrsStatementLineItems [Line Items]
Current assets	417,624		417,624		133,501
Property and equipment	579,393		579,393		573,773
Patents and licenses	523,757		523,757		510,705
Right of use assets	123,513		123,513		185,272
Total assets	1,644,287		1,644,287		1,403,251
Revenue
Selling, marketing and administration			(4,542,054)	(4,280,844)
Research and development			(2,739,509)	(3,099,397)
Interest			(36,392)	(23,699)
Share of loss in joint venture
Gain from contribution of IP to joint venture
Other income, including interest
Net loss			(7,317,955)	(7,403,940)
Canada [member]
IfrsStatementLineItems [Line Items]
Current assets	4,355,815		4,355,815		8,770,035
Property and equipment
Patents and licenses
Right of use assets
Total assets	$ 4,355,815		4,355,815		$ 8,770,035
Revenue
Selling, marketing and administration			(1,205,432)	(1,074,149)
Research and development			(119,641)	(135,470)
Interest
Share of loss in joint venture
Gain from contribution of IP to joint venture
Other income, including interest			180,943	119,728
Net loss			$ (1,144,130)	$ (1,089,891)

SCHEDULE OF CLASSIFIED FINANCIA

SCHEDULE OF CLASSIFIED FINANCIAL ASSETS AND LIABILITIES (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
Notes and other explanatory information [abstract]
Cash and cash equivalents	$ 4,476,478	$ 9,229,845	$ 10,269,148	$ 14,941,775
Accounts receivable		62,842
Accounts payable and accrued liabilities	(1,353,208)	(3,362,430)
Covid-19 government support loans	(29,428)	(29,520)
Contract liabilities	$ (105,263)	$ (274,192)

SCHEDULE OF COMPONENTS OF CAPIT

SCHEDULE OF COMPONENTS OF CAPITAL (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
Notes and other explanatory information [abstract]
Cash and cash equivalents	$ 4,476,478	$ 9,229,845	$ 10,269,148	$ 14,941,775
Shareholders' equity	$ 220,322,204

SCHEDULE OF EXPENSES BY NATURE

SCHEDULE OF EXPENSES BY NATURE (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Notes and other explanatory information [abstract]
Wages and benefits	$ 1,074,549	$ 1,042,347	$ 3,221,450	$ 2,990,224
Subcontract fees	314,296	400,475	1,632,010	1,720,487
Stock-based compensation	406,536	477,224	1,109,171	1,280,702
Supplies	654,419	441,945	1,543,232	1,235,959
Research and development costs	2,449,800	2,361,991	7,505,863	7,227,372
Stock-based compensation	845,112	403,572	2,042,185	1,567,196
Wages and benefits	640,241	646,349	1,973,231	1,983,180
General expenses	387,183	435,990	1,375,911	1,558,810
Professional fees	273,905	203,778	842,403	743,075
Depreciation and amortization	508,484	336,446	1,416,271	952,141
Rent and facility costs	42,274	48,569	123,021	100,219
Selling, marketing and administration costs	$ 2,697,199	$ 2,074,704	$ 7,773,022	$ 6,904,621

FINANCIAL INSTRUMENTS AND RIS_3

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)	9 Months Ended
	Sep. 30, 2023 USD ($)
Notes and other explanatory information [abstract]
Change in exchange rate risk	10%
Increase decrease in other comprehensive loss	$ 8,200

REVENUE (Details Narrative)

REVENUE (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Notes and other explanatory information [abstract]
Revenue		$ 232,928	$ 358,226	$ 353,189